Corporate Actions & Financing | Almirall
Dermatology
- Atopic dermatitis
- Psoriasis
- Actinic keratosis
- Acne
- Other skin conditions
Corporate actions and financing
How we support our growth and strategy
In this section, we offer you a comprehensive view of the corporate actions and financing activities that underpin our long-term development at Almirall. These activities play an essential role in shaping our strategic direction, ensuring financial stability, and supporting our commitment to research, innovation, and sustainable expansion.
Financial data
Dividends evolution
| Year | Gross amount per share (€) | Payment Date | Type |
|---|---|---|---|
| 2024 | 0.18 | 04/06/2025 | Ordinary |
| 2023 | 0.18 | 05/06/2024 | Ordinary |
| 2022 | 0.18 | 31/05/2023 | Ordinary |
| 2021 | 0.19 | 01/06/2022 | Ordinary |
| 2020 | 0.19 | 02/06/2021 | Ordinary |
| 2019 | 0.19 | 01/10/2020 | Ordinary |
| 2018 | 0.18 | 03/06/2019 | Ordinary |
| 2017 | 0.19 | 01/06/2018 | Ordinary |
| 2016 | 0.19 | 01/06/2017 | Ordinary |
| 2015 | 0.19 | 01/06/2016 | Ordinary |
| 2014 | 0.20 | 01/06/2015 | Ordinary |
| 2012 | 0.15 | 05/06/2013 | Ordinary |
| 2011 | 0.17 | 01/06/2012 | Ordinary |
| 2010 | 0.28 | 01/06/2011 | Ordinary |
| 2009 | 0.33 | 01/06/2010 | Ordinary |
| 2008 | 0.31 | 01/06/2009 | Ordinary |
| 2007 | 0.31 | 23/05/2008 | Ordinary |
Our approach to financing
Financing is central to maintaining momentum across our research pipeline, market operations, and international footprint. We maintain a balanced approach to funding, focusing on stability, responsibility, and long-term resilience.
Takeover bids
There are no takeover bids in process or operations with results announced less than one year ago.
Debt issues
For information on current outstanding bonds you can access the LuxSE website.